Aspergillus terreus (AT) and Saccharomyces cerevisiaa (SC) are uncommon but emerging pathogens in the immunocompromised host. AT can be relatively resistant to amphotericin B so alternative therapy is needed. In this invitro evaluation, 28 clinical isolates of SC and 26 clinical isolates of AT were tested against amphotericin B (ampho) and the echinocandin caspofungin (caspo) using broth microdilution methods as described in NCCLS documents M27-A and M38-P to determine susceptibility. MIC and MFC determinations were made. Against the test strains of SC, caspo MIC90 was 5ug/mL, ampho MIC90 1.0; MFC90 caspo 1.0 ug/mL. ampho 2.Oug/mL. Against the teststrains of AT, caspo MIC90 was 0.25ug/mL (48h) and ampho MIC90 was 2.Oug/mL (48h). MFC90 caspo and ampho >16ug/mL. The new echinocandin caspo appears to have excellent invitro activity against these emerging pathogens. Clinical studies appearwarranted.
Full conference title:
Focus on Fungal Infections 11, March 14-16 2001
- Focus on Fungal Infection 11 (2001)